Spyglass Capital Management LLC Decreases Stock Holdings in Ascendis Pharma A/S (NASDAQ:ASND)

Spyglass Capital Management LLC reduced its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 1.5% during the 3rd quarter, Holdings Channel.com reports. The firm owned 652,841 shares of the biotechnology company’s stock after selling 10,047 shares during the quarter. Ascendis Pharma A/S comprises about 6.4% of Spyglass Capital Management LLC’s holdings, making the stock its 2nd largest position. Spyglass Capital Management LLC’s holdings in Ascendis Pharma A/S were worth $97,476,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Westfield Capital Management Co. LP boosted its stake in Ascendis Pharma A/S by 3.4% in the third quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company’s stock valued at $766,523,000 after acquiring an additional 170,942 shares during the last quarter. Avoro Capital Advisors LLC boosted its stake in Ascendis Pharma A/S by 5.8% in the second quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock valued at $572,341,000 after acquiring an additional 229,995 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its stake in Ascendis Pharma A/S by 9.1% in the third quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company’s stock valued at $278,760,000 after acquiring an additional 155,971 shares during the last quarter. Fred Alger Management LLC boosted its stake in Ascendis Pharma A/S by 65.0% in the second quarter. Fred Alger Management LLC now owns 307,073 shares of the biotechnology company’s stock valued at $41,879,000 after acquiring an additional 120,952 shares during the last quarter. Finally, Tri Locum Partners LP boosted its stake in Ascendis Pharma A/S by 102.1% in the second quarter. Tri Locum Partners LP now owns 227,762 shares of the biotechnology company’s stock valued at $31,062,000 after acquiring an additional 115,092 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on ASND shares. TD Cowen reduced their price objective on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating on the stock in a research note on Friday, November 15th. The Goldman Sachs Group raised their price objective on shares of Ascendis Pharma A/S from $180.00 to $200.00 and gave the company a “buy” rating in a research note on Tuesday, September 17th. StockNews.com upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Wells Fargo & Company increased their target price on shares of Ascendis Pharma A/S from $264.00 to $289.00 and gave the stock an “overweight” rating in a report on Tuesday, September 17th. Finally, Citigroup increased their target price on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a “buy” rating in a report on Tuesday, September 17th. Two investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat, Ascendis Pharma A/S presently has an average rating of “Moderate Buy” and an average target price of $191.77.

Ascendis Pharma A/S Stock Up 1.3 %

Shares of NASDAQ:ASND opened at $136.32 on Friday. Ascendis Pharma A/S has a 12 month low of $90.13 and a 12 month high of $161.00. The company’s fifty day simple moving average is $132.55 and its 200 day simple moving average is $132.21. The firm has a market cap of $8.27 billion, a price-to-earnings ratio of -16.87 and a beta of 0.66.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings data on Tuesday, September 3rd. The biotechnology company reported ($2.05) EPS for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The company had revenue of $38.75 million for the quarter, compared to analyst estimates of $94.74 million. Research analysts expect that Ascendis Pharma A/S will post -7.45 earnings per share for the current fiscal year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.